News
FLGT
18.34
-2.19%
-0.41
Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)
Seeking Alpha · 4d ago
Weekly Report: what happened at FLGT last week (1209-1213)?
Weekly Report · 6d ago
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
NASDAQ · 12/09 14:55
Weekly Report: what happened at FLGT last week (1202-1206)?
Weekly Report · 12/09 10:49
Weekly Report: what happened at FLGT last week (1125-1129)?
Weekly Report · 12/02 10:50
Weekly Report: what happened at FLGT last week (1118-1122)?
Weekly Report · 11/25 10:43
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
NASDAQ · 11/22 17:00
New Strong Buy Stocks for November 22nd
NASDAQ · 11/22 11:02
Weekly Report: what happened at FLGT last week (1111-1115)?
Weekly Report · 11/18 10:41
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Dow Jones · 11/11 13:05
Fulgent Genetics Price Target Cut to $22.00/Share From $26.00 by Piper Sandler
Dow Jones · 11/11 13:05
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $22
Benzinga · 11/11 12:54
Fulgent Genetics price target lowered to $22 from $26 at Piper Sandler
TipRanks · 11/11 12:09
Weekly Report: what happened at FLGT last week (1104-1108)?
Weekly Report · 11/11 10:51
FULGENT GENETICS INC <FLGT.O>: PIPER SANDLER CUTS TARGET PRICE TO $22 FROM $26
Reuters · 11/11 04:15
Fulgent Genetics Reports Q3 2024 Financial Performance
TipRanks · 11/09 04:09
Based on the provided financial report, the title of the article is: "Fulgent Genetics, Inc. Reports Financial Results for the Quarter Ended September 30, 2024" Note that this is a quarterly report (Form 10-Q) filed with the Securities and Exchange Commission (SEC) by Fulgent Genetics, Inc., a publicly traded company. The report provides an overview of the company's financial performance for the quarter ended September 30, 2024.
Press release · 11/08 21:12
Fulgent Genetics Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/08 16:21
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
NASDAQ · 11/08 13:15
Fulgent Genetics reports Q3 EPS 31c, consensus (15c)
TipRanks · 11/08 12:32
More
Webull provides a variety of real-time FLGT stock news. You can receive the latest news about Fulgent Genetics through multiple platforms. This information may help you make smarter investment decisions.
About FLGT
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.